Altor Bioscience Corporation

Altor Bioscience Corporation is a biotechnology startup founded in 2002. The company has developed a proprietary technology for producing biologically active, soluble TCR molecules in a single-chain format, known as STAR™ molecules. These molecules have the ability to specifically recognize novel targets on virus-infected or cancerous cells, including intracellular antigens that are not accessible to therapeutic antibodies. Altor has also developed STAR™ fusions with cytokines and antibody-like STAR™ fusions which function as therapeutics. The startup's drug development strategy is aimed at employing the unique antigen recognition properties of the TCR to lower the therapeutic dosage of currently approved drugs and decrease their side effects while maintaining their efficacy. Their goal is to deliver anti-cancer and anti-viral drugs, such as approved immunomodulatory cytokines, cytotoxic drugs, radioisotopes, and imaging agents, directly to diseased cells and tissues. This approach is expected to maximize the chances of success in the clinic by adopting the proven clinical path of these approved drugs for the development of STAR™-based therapeutics. The last investment in Altor Bioscience Corporation was a Private Equity investment on 22nd March 2017. While the specific details of the investors involved in this investment are not disclosed, it signifies a pivotal point in the company's journey, providing financial support and confidence in their innovative biotechnology and pharmaceutical initiatives. The company operates in the Biotechnology, Health and Wellness, and Pharmaceutical industries, positioned at the forefront of cutting-edge advancements in healthcare and therapeutics.